Diabetic Ketoacidosis and Severe Hypoglycemia Risks with Ipragliflozin/Insulin Versus Insulin in Type 1 Diabetes: A Japanese Real-World Database Study.

ABSTRACT:

Introduction

Ipragliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved in Japan as an adjunct to insulin therapy for the management of type 1 diabetes (T1D). Diabetic ketoacidosis (DKA) and severe hypoglycemia (SH) have been specified as important identified risks for ipragliflozin; however, real-world data on the incidences of these events are limited. We compared the incidences of initial DKA and SH in patients with T1D newly treated with ipragliflozin in combination with insulin versus those treated with insulin.

Methods

This post-marketing surveillance study used data from the JMDC Claims Database between June 2018 and December 2021. Using propensity score matching, patients with T1D were matched 1:10 to the ipragliflozin/insulin group and insulin grou

SUBMITTER: Kawamura T 

PROVIDER: S-EPMC12847507 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature